31 results on '"Kim, S. J."'
Search Results
2. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
3. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
4. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
5. Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin
6. 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
7. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?
8. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases
9. Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer
10. Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society
11. Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy
12. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis
13. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers
14. COMPARISON OF HIGH-DOSE CYCLOPHOSPHAMIDE PLUS G-CSF WITH G-CSF ALONE FOR PERIPHERAL BLOOD STEM CELL MOBILIZATION IN MM
15. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma
16. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients
17. 1453P Safety and efficacy of vactosertib, a TGF-βR1 kinase inhibitor, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma
18. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
19. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study
20. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer
21. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type
22. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
23. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas
24. Preclinical study of olmutinib (HM61713) with optimal dosing in ectopic and metastatic mouse model of EGFR-mutant (T790M-positive) non-small cell lung cancer (NSCLC)
25. Usefulness of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia
26. 433P - Preclinical study of olmutinib (HM61713) with optimal dosing in ectopic and metastatic mouse model of EGFR-mutant (T790M-positive) non-small cell lung cancer (NSCLC)
27. 50P - Usefulness of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia
28. Analyses on Safety and Predictive Clinical Parameters for Dosage Modification in Korean Gastric Cancer Patients Receiving Adjuvant S-1 Chemotherapy
29. LBA13Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis.
30. 40OBiomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET).
31. 42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.